Search This Blog

Monday, April 12, 2021

Replimune: New Biomarker, Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at AACR

 Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2

  • Increased infiltration of CD8+ T cells and PD-L1 expression for patients dosed with RP1 in combination with Opdivo® (nivolumab) and single agent RP2 in human biomarker samples

  • Pre-clinical evidence of innate immune activation mediated by GALV-GP R- expression

  • Gene expression profiling supportive of broad immune activation in both humans & mice

  • Further pre-clinical demonstration of potent lytic activity in tumors

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)